BACKGROUND: It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens. METHODS: In this multicenter trial we compared initial therapy involving four-drug regimens containing efavirenz and nelfinavir in combination with either didanosine and stavudine or zidovudine and lamivudine with therapy involving two consecutive three-drug regimens the first of which contained either efavirenz or nelfinavir. RESULTS:A total of 980 subjects were followed for a median of 2.3 years. There was no significant difference in the occurrence of regimen failures between the group that received the four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz and the groups that received the three-drug regimens beginning with didanosine, stavudine, and nelfinavir (hazard ratio for regimen failure, 1.24) or didanosine, stavudine, and efavirenz (hazard ratio, 1.01). There was no significant difference between the group that received the four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz and the groups that received the three-drug regimens beginning with zidovudine, lamivudine, and nelfinavir (hazard ratio, 1.06) or zidovudine, lamivudine, and efavirenz (hazard ratio, 1.45). A four-drug regimen was associated with a longer time to the first regimen failure than the three-drug regimens containing didanosine, stavudine, and nelfinavir (hazard ratio for a first regimen failure, 0.55); didanosine, stavudine, and efavirenz (hazard ratio, 0.63); or zidovudine, lamivudine, and nelfinavir (hazard ratio, 0.49), but not the three-drug regimen containing zidovudine, lamivudine, and efavirenz (hazard ratio, 1.21). CONCLUSIONS: There was no significant difference in the duration of successful HIV-1 treatment between a single four-drug regimen and two consecutive three-drug regimens. Among these treatment strategies, initiating therapy with the three-drug regimen of zidovudine, lamivudine, and efavirenz is the optimal choice. Copyright 2003 Massachusetts Medical Society
RCT Entities:
BACKGROUND: It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens. METHODS: In this multicenter trial we compared initial therapy involving four-drug regimens containing efavirenz and nelfinavir in combination with either didanosine and stavudine or zidovudine and lamivudine with therapy involving two consecutive three-drug regimens the first of which contained either efavirenz or nelfinavir. RESULTS: A total of 980 subjects were followed for a median of 2.3 years. There was no significant difference in the occurrence of regimen failures between the group that received the four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz and the groups that received the three-drug regimens beginning with didanosine, stavudine, and nelfinavir (hazard ratio for regimen failure, 1.24) or didanosine, stavudine, and efavirenz (hazard ratio, 1.01). There was no significant difference between the group that received the four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz and the groups that received the three-drug regimens beginning with zidovudine, lamivudine, and nelfinavir (hazard ratio, 1.06) or zidovudine, lamivudine, and efavirenz (hazard ratio, 1.45). A four-drug regimen was associated with a longer time to the first regimen failure than the three-drug regimens containing didanosine, stavudine, and nelfinavir (hazard ratio for a first regimen failure, 0.55); didanosine, stavudine, and efavirenz (hazard ratio, 0.63); or zidovudine, lamivudine, and nelfinavir (hazard ratio, 0.49), but not the three-drug regimen containing zidovudine, lamivudine, and efavirenz (hazard ratio, 1.21). CONCLUSIONS: There was no significant difference in the duration of successful HIV-1 treatment between a single four-drug regimen and two consecutive three-drug regimens. Among these treatment strategies, initiating therapy with the three-drug regimen of zidovudine, lamivudine, and efavirenz is the optimal choice. Copyright 2003 Massachusetts Medical Society
Authors: S Grabar; C Pradier; E Le Corfec; R Lancar; C Allavena; M Bentata; P Berlureau; C Dupont; P Fabbro-Peray; I Poizot-Martin; D Costagliola Journal: AIDS Date: 2000-01-28 Impact factor: 4.177
Authors: D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: O Gallego; C de Mendoza; M J Pérez-Elías; J M Guardiola; J Pedreira; D Dalmau; J Gónzalez; A Moreno; J R Arribas; A Rubio; I García-Arata; M Leal; P Domingo; V Soriano Journal: AIDS Date: 2001-09-07 Impact factor: 4.177
Authors: L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo Journal: J Virol Date: 2001-06 Impact factor: 5.103
Authors: Hélène C F Côté; Zabrina L Brumme; Kevin J P Craib; Christopher S Alexander; Brian Wynhoven; Lillian Ting; Hubert Wong; Marianne Harris; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: N Engl J Med Date: 2002-03-14 Impact factor: 91.245
Authors: R L Murphy; R M Gulick; V DeGruttola; R T D'Aquila; J J Eron; J P Sommadossi; J S Currier; L Smeaton; I Frank; A M Caliendo; J G Gerber; R Tung; D R Kuritzkes Journal: J Infect Dis Date: 1999-04 Impact factor: 5.226
Authors: Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Jeonnette R Ickovics; Ann Cameron; Robert Zackin; Roland Bassett; Margaret Chesney; Victoria A Johnson; Daniel R Kuritzkes Journal: Antivir Ther Date: 2002-09
Authors: Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: Mary F Kearney; Ann Wiegand; Wei Shao; John M Coffin; John W Mellors; Michael Lederman; Rajesh T Gandhi; Brandon F Keele; Jonathan Z Li Journal: J Virol Date: 2015-11-18 Impact factor: 5.103
Authors: Patrick F Smith; Gregory K Robbins; Robert W Shafer; Hulin Wu; Song Yu; Martin S Hirsch; Thomas C Merigan; Jeong-Gun Park; Alan Forrest; Margaret A Fischl; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick Journal: Clin Infect Dis Date: 2013-09-17 Impact factor: 9.079
Authors: Ye Ma; Decai Zhao; Lan Yu; Marc Bulterys; Matthew L Robinson; Yan Zhao; Zhihui Dou; Philippe Chiliade; Xiaoyu Wei; Fujie Zhang Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079